Fluconazole 150 mg tab — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Candidiasis (Vulvovaginal/Oral)

• Clotrimazole
• Nystatin oral suspension
• Clotrimazole 1% cream
• Nystatin oral suspension 100,000 U/mL

About Fluconazole 150 mg tab

Dealing with a yeast infection can be uncomfortable and disruptive. Fluconazole 150 mg is a widely prescribed, single-dose oral medication known for its effectiveness in treating these common infections. At TheDrugClub, we believe essential medications like fluconazole should be affordable and accessible, which is why our members can get it for $0 co-pay.

What is Fluconazole 150 mg and What Does It Treat?

Fluconazole 150 mg is an antifungal medication primarily used to treat vaginal yeast infections, also known as vulvovaginal candidiasis. These infections are caused by an overgrowth of a fungus called *Candida*, leading to symptoms like itching, burning, and discharge. While often associated with vaginal infections, fluconazole can also be prescribed for other fungal infections in various parts of the body, though the 150 mg dose is specifically tailored for uncomplicated vaginal yeast infections. Its convenience as a single-dose oral tablet makes it a popular choice for quick relief and effective treatment.

How Does Fluconazole Work?

Fluconazole belongs to a class of drugs called azole antifungals. It works by inhibiting an enzyme in the fungal cells that is essential for the production of ergosterol. Ergosterol is a vital component of

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Fluconazole 150 mg tab is approved for (FDA label)

Fluconazole is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms.

Source: Read the full FDA label on DailyMed. Label effective date: April 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fluconazole 150 mg tab (FDA label)

Fluconazole is generally well tolerated. In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain. In Patients Receiving a Single Dose for Vaginal Candidiasis During comparative clinical studies conducted in the United States, 448 patients with vaginal candidiasis were treated with fluconazole, 150 mg single dose.

Source: FDA prescribing information (DailyMed). Set ID: 737e0fac-a2d2-4053-a0d7-edbfb6248f69. SPL document ID: 5a926244-1653-4a4e-9a60-9713a91d2485. Label effective date: April 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fluconazole 150 mg tab (FDA label)

Fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and PRECAUTIONS . )

Source: FDA prescribing information (DailyMed). Set ID: 737e0fac-a2d2-4053-a0d7-edbfb6248f69. SPL document ID: 5a926244-1653-4a4e-9a60-9713a91d2485. Label effective date: April 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fluconazole 150 mg tab (FDA label)

WARNINGS (1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed. Fluconazole hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury. Fluconazole should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole. (2) Anaphylaxis: In rare cases, anaphylaxis has been reported. (3) Dermatologic: Exfoliative skin disorders during treatment with fluconazole have been reported. Fatal outcomes have been reported in patients with serious underlying diseases.

Source: FDA prescribing information (DailyMed). Set ID: 737e0fac-a2d2-4053-a0d7-edbfb6248f69. SPL document ID: 5a926244-1653-4a4e-9a60-9713a91d2485. Label effective date: April 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fluconazole 150 mg tab (FDA label)

Drug Interactions (See CONTRAINDICATIONS . ) Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor. Fluconazole is also a strong inhibitor of CYP2C19. Patients treated with fluconazole, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs. In addition to the observed /documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4 to 5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole.

Source: FDA prescribing information (DailyMed). Set ID: 737e0fac-a2d2-4053-a0d7-edbfb6248f69. SPL document ID: 5a926244-1653-4a4e-9a60-9713a91d2485. Label effective date: April 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.